An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection

Photochemistry and Photobiology

Volumn 87, Issue 6, 2011, Pages 1419-1426

  Blake, Emma ^a   Allen, James ^a   Curnow, Alison ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXYPYRIDIN 4 ONE; 1,2-DIETHYL-3-HYDROXYPYRIDIN-4-ONE; IRON CHELATING AGENT; PROTOPORPHYRIN; PYRIDONE DERIVATIVE; RAZOXANE;

ARTICLE; COMPARATIVE STUDY; FLUORESCENCE; HUMAN; IN VITRO STUDY; METABOLISM; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

CELL LINE, TUMOR; FLUORESCENCE; HUMANS; IRON CHELATING AGENTS; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS; PYRIDONES; RAZOXANE;

EID: 80055017713     PISSN: 00318655     EISSN: 17511097     Source Type: Journal    
DOI: 10.1111/j.1751-1097.2011.00985.x     Document Type: Article

References (39)

1. Pass, H. I., (1993) Photodynamic therapy in oncology: Mechanisms and clinical use. J. Natl Cancer Inst. 85, 443-456. (Pubitemid 23084089)
2. Liu, H. F., S. Z. Xu, and, C. R. Zhang, (2004) Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. Chin. Med. J. (Engl.) 117, 922-926.
3. Szeimies, R. M., P. Calzavara-Pinton, S. Karrer, B. Ortel, and, M. Landthaler, (1996) Topical photodynamic therapy in dermatology. J. Photochem. Photobiol. B 36, 213-219. (Pubitemid 27011272)
4. Pye, A., Y. Dogra, J. Tyrrell, P. Winyard, and, A. Curnow, (2009) Redox signaling and regulation in biology and medicine. In Photodynamic Therapy with Aminolevulinic Acid and Iron Chelators: A Clinical Example of Redox Signaling (Edited by, C. Jacob, and, P. Winyard,), pp. 351-372. Wiley-VCH, Weinheim, Germany.
5. Dailey, H. A., and, A. Smith, (1984) Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochem. J. 223, 441-445. (Pubitemid 14023016)
6. el-Sharabasy, M. M., A. M. el-Waseef, M. M. Hafez, and, S. A. Salim, (1992) Porphyrin metabolism in some malignant diseases. Br. J. Cancer 65, 409-412.
7. Gibson, S. L., D. J. Cupriks, J. J. Havens, M. L. Nguyen, and, R. Hilf, (1998) A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization? Br. J. Cancer 77, 235-242. (Pubitemid 28029540)
8. Kennedy, J. C., R. H. Pottier, and, D. C. Pross, (1990) Photodynamic therapy with endogenous protoporphyrin: IX: Basic principles and present clinical experience. J. Photochem. Photobiol. B: Biol. 6, 143-148.
9. Rhodes, L. E., M. de Rie, Y. Enstrom, R. Groves, T. Morken, V. Goulden, G. A. Wong, J. J. Grob, S. Varma, and, P. Wolf, (2004) Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial. Arch. Dermatol. 140, 17-23. (Pubitemid 38090266)
10. Curnow, A., and, A. Pye, (2007) Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors. J. Environ. Pathol. Toxicol. Oncol. 26, 89-103. (Pubitemid 47295561)
11. Muller, P. J., and, B. C. Wilson, (2006) Photodynamic therapy of brain tumors-a work in progress. Lasers Surg. Med. 38, 384-389.
12. Frieboes, H. B., J. S. Lowengrub, S. Wise, X. Zheng, P. Macklin, E. L. Bearer, and, V. Cristini, (2007) Computer simulation of glioma growth and morphology. NeuroImage 37, 59-70.
13. Madsen, S. J., C. H. Sun, B. J. Tromberg, V. P. Wallace, and, H. Hirschberg, (2000) Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid. Photochem. Photobiol. 72, 128-134.
14. Stummer, W., S. Stocker, A. Novotny, A. Heimann, O. Sauer, O. Kempski, N. Plesnila, J. Wietzorrek, and, H. J. Reulen, (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J. Photochem. Photobiol. B 45, 160-169. (Pubitemid 28550192)
15. von Beckerath, M., P. Juzenas, L. W. Ma, V. Iani, L. Lofgren, and, J. Moan, (2001) The influence of UV exposure on 5-aminolevulinic acid-induced protoporphyrin IX production in skin. Photochem. Photobiol. 74, 825-828.
16. Kaneko, S., (2008) Recent advances in PDD and PDT for malignant brain tumours. Rev. Laser Eng. 36, 1351-1354.
17. Stummer, W., S. Stocker, S. Wagner, H. Stepp, C. Fritsch, C. Goetz, A. E. Goetz, R. Kiefmann, and, H. J. Reulen, (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42, 518-525. Discussion 525-6.
18. Chang, S. C., A. J. MacRobert, J. B. Porter, and, S. G. Bown, (1997) The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: An in vivo study. J. Photochem. Photobiol. B 38, 114-122. (Pubitemid 27277866)
19. Pye, A., and, A. Curnow, (2007) Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochem. Photobiol. 83, 766-773. (Pubitemid 46854964)
20. Hanania, J., and, Z. Malik, (1992) The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. Cancer Lett. 65, 127-131.
21. Sandeman, D. R., R. Bradford, P. Buxton, S. G. Bown, and, D. G. Thomas, (1987) Selective necrosis of malignant gliomas in mice using photodynamic therapy. Br. J. Cancer 55, 647-649. (Pubitemid 17090974)
22. Junjing, Z., Z. Yan, and, Z. Baolu, (2010) Scavenging effects of dexrazoxane on free radicals. J. Clin. Biochem. Nutr. 47, 238-245.
23. Buss, J. L., and, B. B. Hasinoff, (1995) Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Arch. Biochem. Biophys. 317, 121-127.
24. Blake, E., and, A. Curnow, (2010) The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem. Photobiol. 86, 1154-1160.
25. Curnow, A., B. W. McIlroy, M. J. Postle-Hacon, J. B. Porter, A. J. MacRobert, and, S. G. Bown, (1998) Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br. J. Cancer 78, 1278-1282. (Pubitemid 28495237)
26. Campbell, S. M., C. A. Morton, R. Alyahya, S. Horton, A. Pye, and, A. Curnow, (2008) Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br. J. Dermatol. 159, 387-393. (Pubitemid 352009857)
27. Peng, Q., A. M. Soler, T. Warloe, J. M. Nesland, and, K. E. Giercksky, (2001) Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J. Photochem. Photobiol. B 62, 140-145. (Pubitemid 32898834)
28. Dawson, K. M., (1975) Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 24, 2249-2253.
29. Hasinoff, B. B., (1990) The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Drug Metab. Dispos. 18, 344-349. (Pubitemid 20174249)
30. Hasinoff, B. B., (1994) Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 83, 64-67. (Pubitemid 24233732)
31. Hasinoff, B. B., F. X. Reinders, and, V. Clark, (1991) The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab. Dispos. 19, 74-80.
32. Hasinoff, B. B., (1993) Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos. 21, 883-888. (Pubitemid 23298456)
33. Hasinoff, B. B., (1990) The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Agents Actions 29, 374-381. (Pubitemid 20098468)
34. Valdes, P. A., K. Samkoe, J. A. O'Hara, D. W. Roberts, K. D. Paulsen, and, B. W. Pogue, (2010) Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem. Photobiol. 86, 471-475.
35. Fredenburg, A. M., R. K. Sethi, D. D. Allen, and, R. A. Yokel, (1996) The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4- one in the rat. Toxicology 108, 191-199.
36. Hofland, K. F., A. V. Thougaard, M. Dejligbjerg, L. H. Jensen, P. E. G. Kristjansen, P. Rengtved, M. Sehested, and, P. B. Jensen, (2005) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin. Cancer Res. 11, 6722-6729. (Pubitemid 41339015)
37. Inamura, T., and, K. L. Black, (1994) Bradykinin selectively opens blood-brain barrier in tumors. J. Cereb. Blood Flow Metab. 14, 862-870. (Pubitemid 24266539)
38. Brigger, I., J. Morizet, G. Aubert, H. Chacun, M.-J. Terrier-Lacombe, P. Couvreur, and, G. Vassal, (2002) Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumour targeting. JPET 303, 928-936. (Pubitemid 35424373)
39. Bartosova, J., and, Z. Hrkal, (2000) Accumulation of protoporphyrin-IX (PpIX) in leukemic cell lines following induction by 5-aminolevulinic acid (ALA). Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 126, 245-252. (Pubitemid 30665522)